ISU Abxis
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
ISU Abxis develops and supplies biopharmaceutical drugs, medicines derived from living cells rather than chemical synthesis, for use in treating serious diseases.
Its products are supplied to patients and healthcare providers, and the company operates as a standalone entity with no consolidated subsidiaries. It is listed on KOSDAQ, South Korea's technology and small-cap stock exchange.
Summary is AI-generated and may contain errors · figures from DART filings
ISU Abxis in five facts
What does ISU Abxis do?
ISU Abxis develops and supplies biopharmaceutical drugs, medicines derived from living cells rather than chemical synthesis, for use in treating serious diseases.
Where is ISU Abxis listed and in which sector?
ISU Abxis (Korean name: 이수앱지스) trades under KRX code 086890 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is ISU Abxis?
Its market capitalisation was US$115.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were ISU Abxis's latest annual revenue and operating profit?
For fiscal year 2025, ISU Abxis reported revenue of US$42.8M, operating profit of US$1.2M and a net loss of US$8.1M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 6.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Sep 22
- Operating results (preliminary) (fair disclosure)
ISU Abxis filed provisional (unaudited) separate results for Q2 2026: revenue of US$10.5M (−34.6% year on year), operating profit of US$337K (−94.9% year on year) and net income of US$2.23M (−65.7% year on year).
Earnings · Aug 6 - [Amended] Supply contract signed
ISU Abxis updated a previously disclosed supply contract with BL HUA&Co.,LTD., now worth US$456K, about 19.95% of its recent annual revenue, running through Jun 2027.
Supply contract · Jun 17 - Operating results (preliminary) (fair disclosure)
ISU Abxis filed provisional (unaudited) separate results for Q1 2026: revenue of US$6.5M (+31.6% year on year), an operating loss of US$2.37M and a net loss of US$139K.
Earnings · May 7 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Mar 23
- [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
ISU Abxis updated its previously filed separate results for FY2025: revenue of US$38.8M (−6% year on year), operating profit of US$1.12M (−87.8% year on year) and a net loss of US$7.31M (from a profit a year earlier).
Earnings · Feb 5 · 2 versions